Skip to main content

Table 6 Late toxicity assessment (based on Modified LENT SOMA)

From: A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects

 

G1

G2

G3

G4

N0 of patients

At 6 months (subacute)

     

   Hyperpigmentation

22 (34%)

4 (6%)

0

0

65

At 12 months

     

   Fibrosis

28 (43%)

2 (3%)

0

0

65

   Hyperpigmentation

3 (5%)

0

0

0

65

At 24 months*

     

   Fibrosis

25 (45%)

2 (3%)

0

0

56

   Hyperpigmentation

0

0

0

0

56

  1. * A total of 56 patients seen at 24 months or more with 29 (52%) free of side effects.